Lixte Biotechnology Holdings, Inc. (LIXT), Friday announced a partnership with Swiss healthcare company Roche Holding AG (RHHBY) and the Netherlands Cancer Institute to conduct a new clinical trial for immune therapy unresponsive metastatic colon cancer.
In the trial listed as NCT06012734, Lixte will contribute its lead compound LB-100, which helps in enhancing response to immunotherapy, whereas Roche will provide atezolizumab and financial support.
Currently, LIXTE's stock is moving up 8.6 percent, to $2.8 on the Nasdaq.
For comments and feedback contact: editorial@rttnews.com
Health News
April 17, 2026 15:29 ET The ongoing conflict in the Middle East continues to raise concerns for policymakers who worry about the impact of the supply shock and high energy prices on the real economy. Producer price data and various survey results on the housing market were the main news from the U.S. this week. In Europe, industrial production data for the euro area gained attention. GDP figures out of China and the policy move by the Singapore central bank were in focus in Asia.